1
Clinical Trials associated with QAK-423A Randomized, Double-blind, Placebo-controlled Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of QAK423 in Healthy Subjects and COPD Patients and Multiple, Titrated Dosing in COPD Patients
There are three elements to this study:
Part A: Single dose escalation in healthy subjects. 6 dose levels of QAK423 are planned in healthy volunteers.
Part B: Single dose escalation in patients with mild/moderate COPD. 3 dose levels of QAK423 are planned in COPD patients.
Part C: Titrated repeat dosing for a maximum of 14 days in mild/moderate COPD patients.
Repeat dosing is planned in COPD patients.
100 Clinical Results associated with QAK-423
100 Translational Medicine associated with QAK-423
100 Patents (Medical) associated with QAK-423
100 Deals associated with QAK-423